GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zomedica Corp (AMEX:ZOM) » Definitions » Net Cash per Share

Zomedica (Zomedica) Net Cash per Share : $0.08 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Zomedica Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Zomedica's Net Cash per Share for the quarter that ended in Dec. 2023 was $0.08.

The historical rank and industry rank for Zomedica's Net Cash per Share or its related term are showing as below:

ZOM' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.61   Med: 2.5   Max: 66
Current: 1.75

During the past 11 years, the highest Price-to-Net-Cash Ratio of Zomedica was 66.00. The lowest was 1.61. And the median was 2.50.

ZOM's Price-to-Net-Cash is ranked better than
88.86% of 341 companies
in the Medical Devices & Instruments industry
Industry Median: 7.03 vs ZOM: 1.75

Zomedica Net Cash per Share Historical Data

The historical data trend for Zomedica's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zomedica Net Cash per Share Chart

Zomedica Annual Data
Trend Feb14 Feb15 Feb16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 0.07 0.19 0.10 0.08

Zomedica Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.11 0.12 0.09 0.08

Competitive Comparison of Zomedica's Net Cash per Share

For the Medical Devices subindustry, Zomedica's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zomedica's Price-to-Net-Cash Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Zomedica's Price-to-Net-Cash falls into.



Zomedica Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Zomedica's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(90.497-13.18-0)/979.95
=0.08

Zomedica's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(90.497-13.18-0)/979.95
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zomedica  (AMEX:ZOM) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Zomedica Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Zomedica's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zomedica (Zomedica) Business Description

Traded in Other Exchanges
N/A
Address
100 Phoenix Drive, Suite 125, Ann Arbor, MI, USA, 48108
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is currently focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments: Diagnostic & Therapeutics. It earns the majority of revenue from the therapeutics segment.
Executives
Johnny D Powers director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Heaton Larry C Ii officer: President C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Russell Kevin Klass officer: Vice President of Sales C/O ZOMEDICA CORP, PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Peter Donato officer: Chief Financial Officer 9172 ETON AVENUE, CHATSWORTH CA 91311
Pamela Nichols director 14841 EAST WILDCAT DR., SCOTTSDALE AZ 85262
Karen Dehaan-fullerton officer: Chief Counsel and Secretary C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Anthony K Blair officer: Chief Operating Officer NEOPROBE CORPORATION, 425 METRO PLACE NORTH #300, DUBLIN OH 43017
Adrian Lock officer: VP and General Manager C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Sean Whelan director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Robert Cohen officer: Interim CEO C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Ann Cotter officer: Chief Financial Officer & Sec. C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108
Stephanie Morley officer: COO & VP of Product Dev C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Christopher Ross Macleod director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Christopher Wolfenberg director C/O ZOMEDICA PHARMACEUTICALS CORP, 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108
Gerald Jr Solensky director, 10 percent owner, officer: President and CEO C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 190, ANN ARBOR MI 48108